Table 2 Comparison of HCV Treatment Naïve and HCV-Treated HCC patients
Parameter | All HCV-HCC (n = 171) | TN (n = 120) | TH (n = 51) | Crude Odds | 95% CI | P-value1 | |
|---|---|---|---|---|---|---|---|
Age (yr) | > 55 | 98 (57.3) | 77 (64.2) | 21 (41.2) | Reference | – | 0.005 |
≤ 55 | 73 (42.7) | 43 (35.8) | 30 (58.8) | 2.56 | 1.30 to 5.00 | ||
Sex | Female | 63 (36.8) | 41 (34.2) | 22 (43.1) | Reference | – | 0.266 |
Male | 108 (63.2) | 79 (65.8) | 29 (56.9) | 0.68 | 0.35 to 1.34 | ||
Tobacco | No | 73 (42.7) | 47 (39.2) | 26 (51.0) | Reference | – | 0.153 |
Yes | 98 (57.3) | 73 (60.8) | 25 (49.0) | 0.62 | 0.32 to 1.19 | ||
DM | No | 118 (69.6) | 87 (73.1) | 31 (60.8) | Reference | – | 0.110 |
Yes | 52 (30.4) | 32 (26.9) | 20 (39.2) | 1.75 | 0.87 to 3.51 | ||
TBIL (mg/dL) | ≤ 1.5 | 76 (44.4) | 51 (42.5) | 25 (49.0) | Reference | – | 0.432 |
> 1.5 | 95 (55.6) | 69 (57.5) | 26 (51.0) | 0.77 | 0.39 to 1.48 | ||
Albumin (g/dL) | > 3.5 | 22 (12.9) | 15 (12.5) | 7 (13.7) | Reference | – | 0.369 |
2.8–3.5 | 94 (55.0) | 70 (40.9) | 24 (14.0) | 0.74 | 0.26 to 2.02 | ||
< 2.8 | 55 (32.2) | 35 (20.5) | 20 (11.7) | 1.22 | 0.43 to 3.51 | ||
ALT (IU/L) | ≤ 56 | 94 (55) | 64 (53.3) | 30 (58.8) | Reference | – | 0.509 |
> 56 | 77 (45) | 56 (46.7) | 21 (41.2) | 0.80 | 0.41 to 1.55 | ||
ALKP (IU/L) | ≤ 125 | 26 (15.2) | 16 (13.3) | 10 (19.6) | Reference | – | 0.296 |
> 125 | 145 (84.8) | 104 (86.7) | 41 (80.4) | 0.63 | 0.26 to 1.50 | ||
Plt (× 109/L) | ≥ 150 | 57 (33.3) | 48 (40.0) | 9 (17.6) | Reference | – | 0.005 |
< 150 | 114 (66.7) | 72 (60.0) | 42 (82.4) | 3.11 | 1.38 to 6.97 | ||
NLR | ≤ 2.5 | 57 (33.3) | 46 (38.3) | 11 (21.6) | Reference | – | 0.033 |
> 2.5 | 114 (66.7) | 74 (61.7) | 40 (78.4) | 2.26 | 1.05 to 4.84 | ||
CTP Class | Class A | 33 (19.3) | 25 (20.8) | 8 (15.7) | Reference | – | 0.257 |
Class B | 89 (52.0) | 65 (54.2) | 24 (47.1) | 1.15 | 0.46 to 2.91 | ||
Class C | 49 (28.7) | 30 (25.0) | 19 (37.3) | 1.98 | 0.74 to 5.28 | ||
Liver Size | Normal | 51 (29.8) | 37 (30.8) | 14 (27.5) | Reference | – | 0.386 |
Enlarge | 56 (32.7) | 42 (35.0) | 14 (27.5) | 0.88 | 0.37 to 2.09 | ||
Decrease | 64 (37.4) | 41 (34.2) | 23 (45.1) | 1.48 | 0.67 to 3.29 | ||
BCLC Stage 2 | Stage A | 27 (15.8) | 20 (16.7) | 7 (13.7) | Reference | – | 0.032 |
Stage B | 17 (9.9) | 11 (9.2) | 6 (11.8) | 1.56 | 0.418 to 5.80 | ||
Stage C | 65 (38.0) | 53 (44.2) | 12 (23.5) | 0.65 | 0.22 to 1.88 | ||
Stage D | 62 (36.3) | 36 (30.0) | 26 (51.0) | 2.06 | 0.76 to 5.59 | ||
MTD (cm) | < 4.45 | 81 (47.4) | 55 (45.8) | 26 (51.0) | Reference | – | 0.816 |
4.45–9.6 | 73 (42.7) | 53 (44.2) | 20 (39.2) | 0.80 | 0.40 to 1.60 | ||
> 9.6 | 17 (9.9) | 5 (9.8) | 12 (10.0) | 0.88 | 0.28 to 2.76 | ||
AFP (ng/dL) | < 100 | 74 (43.3) | 55 (45.8) | 19 (37.3) | Reference | – | 0.049 |
100–1000 | 63 (36.8) | 47 (39.2) | 16 (31.4) | 0.985 | 0.46 to 2.13 | ||
> 1000 | 34 (19.9) | 18 (15.0) | 16 (31.4) | 2.573 | 1.10 to 6.03 | ||
PVT | No | 120 (70.2) | 96 (80.0) | 24 (47.1) | Reference | – | 0.000 |
Yes | 51 (29.8) | 24 (20.0) | 27 (52.9) | 4.500 | 2.22 to 9.14 | ||
Nodules | ≤ 3 | 87 (50.9) | 70 (58.3) | 17 (33.3) | Reference | – | 0.003 |
> 3 | 84 (49.1) | 50 (41.7) | 31 (66.7) | 2.800 | 1.41to 5.56 | ||
AgI | Score = 4 | 22 (12.9) | 20 (16.7) | 2 (3.9) | Reference | – | 0.000 |
Score 5–8 | 108 (63.2) | 81 (67.5) | 27 (52.9) | 3.33 | 0.73 to 15.20 | ||
Score > 8 | 41 (24.0) | 19 (15.8) | 22 (43.1) | 11.58 | 2.39 to 56.09 |